🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Andreas Saltos

Moffitt Cancer Center

ORCID: 0000-0003-3622-026X
MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial”.

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

The Lancet Oncology(2024)10.1016/s1470-2045(24)00064-0
N/A
3.7DataRank · unranked
164 citations

Enriqueta Felip, Dipesh Uprety, Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz‐Ares +15 more

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7
N/A
0.769DataRank · unranked
168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps9638
N/A
0.104DataRank · unranked
1 citations

Richard D. Hall, Andreas Saltos, Gregory A. Otterson, Ming Tan, Sacha Gnjatic +5 more

Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity

Cancer Immunology Research(2023)10.1158/2326-6066.cir-22-0927
N/A
0DataRank · unranked
17 citations

Xiaoqing Yu, Mohammed L. Ibrahim, Dana Foresman, Mengyu Xie, Joseph Johnson +9 more

Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy

Cancers(2023)10.3390/cancers15092521
N/A
0DataRank · unranked
4 citations

Andreas Saltos, Trevor Rose, Zachary Thompson, Ram Thapa, Alberto Chiappori +2 more

6MO: Safety and clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology(2025)10.1016/s1556-0864(25)00201-1
N/A
0DataRank · unranked
16 citations

Dehan Hong, Jia Luo, S-H.I. Ou, M.L. Johnson, A.I. Spira +10 more